What does ohtuvayre — total revenues and income mean?

This metric represents the aggregate financial inflows generated by the Ohtuvayre product line, including royalties, milestone payments, and licensing fees. It serves as a key indicator of the commercial adoption and market performance of this specific therapeutic asset within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the asset independent of the broader corporate results.

Ligand Pharmaceuticals LGND Ohtuvayre — Total revenues and income

Other product segments

Filspari

$11.32M+114%

Captisol

$8.65M—

Kyprolis

$6.74M—

Qarziba

$6.3M+15.7%

Evomela

$5.94M-31.5%

Rylaze

$3.81M+3.7%

Ohtuvayre inventors

$3.05M—

Other

$2.59M—

Teriparatide injection

$2.03M+19.2%

Capvaxive

$1.97M—

Vaxneuvance

$1.61M+25.3%

Contract revenue

$110K—

Similar metrics at other companies

AMGNOtezla — Total revenues

$431M-1.4%

BLCOOTC — Total revenues

$444M+8.6%

BIIBRoyalty Attributed To OCREVUS — Total Revenue

$317.2M+9.8%

BMRNROCTAVIAN — Total revenues

$2.64M-74.9%

GILDOdefsey — Total revenues

$221M-21.4%

UTHROrenitram — Total revenues

$135.6M+12.3%

Other financials

Income statement

See full

Revenue$51.7M+14.1%

Operating income$17.4M+148%

Net income-$13.3M+68.6%

EPS (diluted)-$0.67+69.7%

Balance sheet

See full

Cash & equivalents$115.1M+140%

Total debt$5.1M+14.2%

Total equity$997.3M+25.4%

Total assets$1.5B+69.2%

Cash flow

See full

Operating cash flow$48.7M+291%

CapEx$228.0K+6.5%

Free cash flow$48.5M+289%

Valuation

See full

Market cap$5.51B+96.7%

Enterprise value$5.4B+95.4%

P/E35.9×—

P/S20.1×+4.6×

Profitability

See full

Gross margin91.9%—

Operating margin34.5%+23.0pp

Net margin55.9%+35.7pp

FCF margin44.8%+16.8pp

Returns & leverage

See full

Return on equity17.1%+11.5pp

Debt / equity0×0.0×

Current ratio21.3×+16.0×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ligand Pharmaceuticals's ohtuvayre — total revenues and income.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ligand Pharmaceuticals's ohtuvayre — total revenues and income?: Ligand Pharmaceuticals (LGND) reported ohtuvayre — total revenues and income of $2.99M in Q1 2026.
What does ohtuvayre — total revenues and income mean?: This metric represents the aggregate financial inflows generated by the Ohtuvayre product line, including royalties, milestone payments, and licensing fees. It serves as a key indicator of the commercial adoption and market performance of this specific therapeutic asset within the company's portfolio. Tracking this figure allows investors to assess the revenue contribution and growth trajectory of the asset independent of the broader corporate results.